232 related articles for article (PubMed ID: 26846208)
1. Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.
Calza L; Colangeli V; Manfredi R; Bon I; Re MC; Viale P
J Antimicrob Chemother; 2016 Jun; 71(6):1451-65. PubMed ID: 26846208
[TBL] [Abstract][Full Text] [Related]
2. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
Calza L; Manfredi R; Chiodo F
J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
[TBL] [Abstract][Full Text] [Related]
3. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management.
Calza L; Manfredi R; Chiodo F
Int J Antimicrob Agents; 2003 Aug; 22(2):89-99. PubMed ID: 12927947
[TBL] [Abstract][Full Text] [Related]
4. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
Calza L; Manfredi R; Chiodo F
Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
[TBL] [Abstract][Full Text] [Related]
5. Dyslipidemia related to antiretroviral therapy.
Estrada V; Portilla J
AIDS Rev; 2011; 13(1):49-56. PubMed ID: 21412389
[TBL] [Abstract][Full Text] [Related]
6. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
Calza L; Manfredi R; Pocaterra D; Chiodo F
J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
[TBL] [Abstract][Full Text] [Related]
7. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
[TBL] [Abstract][Full Text] [Related]
8. HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies.
Nolan DP; O'Connor MB; O'Connor C; Moriarty M; O'Leary A; Bergin C
Int J STD AIDS; 2010 Jan; 21(1):75-6. PubMed ID: 19884356
[No Abstract] [Full Text] [Related]
9. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
11. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
12. Dyslipidemia in HIV-infected individuals.
Sprinz E; Lazzaretti RK; Kuhmmer R; Ribeiro JP
Braz J Infect Dis; 2010; 14(6):575-88. PubMed ID: 21340298
[TBL] [Abstract][Full Text] [Related]
13. Combination antiretroviral therapy.
Domingo P; Vidal F
Expert Opin Pharmacother; 2011 May; 12(7):995-8. PubMed ID: 21434758
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular implications of HIV-induced dyslipidemia.
Giannarelli C; Klein RS; Badimon JJ
Atherosclerosis; 2011 Dec; 219(2):384-9. PubMed ID: 21722900
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
Leonard EG; McComsey GA
Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
[TBL] [Abstract][Full Text] [Related]
16. Treatment of dyslipidaemia in HIV-infected persons.
Manuel O; Thiébaut R; Darioli R; Tarr PE
Expert Opin Pharmacother; 2005 Aug; 6(10):1619-45. PubMed ID: 16086650
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk and dyslipidemia among persons living with HIV: a review.
Maggi P; Di Biagio A; Rusconi S; Cicalini S; D'Abbraccio M; d'Ettorre G; Martinelli C; Nunnari G; Sighinolfi L; Spagnuolo V; Squillace N
BMC Infect Dis; 2017 Aug; 17(1):551. PubMed ID: 28793863
[TBL] [Abstract][Full Text] [Related]
18. [HIV infection: emerging issues and new challenges].
Calza L; Manfredi R; Chiodo F
Recenti Prog Med; 2006 Dec; 97(12):771-80. PubMed ID: 17252736
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.
Rimland D; Guest JL; Hernández I; Del Rio C; Le NA; Brown WV
HIV Med; 2005 Sep; 6(5):326-33. PubMed ID: 16156880
[TBL] [Abstract][Full Text] [Related]
20. Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.
Bednasz C; Luque AE; Zingman BS; Fischl MA; Gripshover BM; Venuto CS; Gu J; Feng Z; DiFrancesco R; Morse GD; Ma Q
Curr Vasc Pharmacol; 2016; 14(3):280-7. PubMed ID: 26733388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
